SubHero Banner

bamlanivimab – Emergency use authorization revoked

April 16, 2021 - The FDA revoked the emergency use authorization (EUA) for Eli Lilly’s bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and certain pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 vial testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

Download PDF